15 completed, 7 recruiting, 3 active not recruiting, 2 terminated. 28 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 28 | Completed 15, Recruiting 7, Active not recruiting 3, Terminated 2, Unknown 1 |
| Phase 2 | 5 | Completed 4, Active not recruiting 1 |
Follow Alopecia Areata: new trials by email Literature Review of Alopecia Areata trials Research Report on Alopecia Areata
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata Upadacitinib, Placebo - Severe Alopecia Areata | Phase 3 | Recruiting | AbbVie | 300 | 2026-08-24 | 2026-10-27 |
| A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - Alopecia Areata | Phase 3 | Recruiting | Pfizer | 336 | 2026-07-30 | 2026-10-26 |
| Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata Deuruxolitinib, Placebo - Alopecia Areata | Phase 3 | Recruiting | Sun Pharma Japan Limited | 78 | 2026-06-19 | 2026-10-30 |
| A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata. Ritlecitinib higher dose, Ritlecitinib lower dose - Severe Alopecia Areata | Phase 3 | Recruiting | Pfizer | 140 | 2025-09-10 | 2026-10-15 |
| Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata Deuruxolitinib, Placebo - Alopecia Areata | Phase 3 | Recruiting | Sun Pharmaceutical Industries, Inc. | 355 | 2025-08-05 | 2026-01-28 |
| A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata Ritlecitinib higher dose, Ritlecitinib lower dose, Placebo - Severe Alopecia Areata | Phase 3 | Active not recruiting | Pfizer | 208 | 2025-07-31 | 2026-08-26 |
| A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata Upadacitinib, Upadacitinib Placebo - Alopecia Areata | Phase 3 | Active not recruiting | AbbVie | 125 | 2025-06-19 | 2026-07-30 |
| A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg - Alopecia Areata | Phase 3 | Recruiting | Pfizer | 674 | 2025-04-01 | 2026-10-20 |
| DPCP for the Treatment of Alopecia Areata Diphenylcyclopropenone (DPCP) Ointment - Alopecia Areata | Phase 3 | Terminated | University of Minnesota | 4 | 2024-04-01 | 2026-01-26 |
| A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata Upadacitinib, Placebo - Alopecia Areata | Phase 3 | Recruiting | AbbVie | 1500 | 2023-10-11 | 2026-10-19 |
| Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi. Tofacitinib - Alopecia Areata, Alopecia Totalis | Phase 3 | Completed | Jinnah Hospital | 30 | 2023-07-01 | 2024-02-26 |
| Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata SHR0302, Placebo - Alopecia Areata | Phase 3 | Unknown | Reistone Biopharma Company Limited | 330 | 2022-04-18 | 2023-09-05 |
| Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata Jaktinib - Alopecia Areata | Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 315 | 2022-03-25 | 2025-03-18 |
| European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata CTP-543 - Alopecia Areata | Phase 3 | Completed | Sun Pharmaceutical Industries, Inc. | 407 | 2021-10-19 | 2025-11-21 |
| Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata Jaktinib, placebo - Alopecia Areata | Phase 3 | Completed | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 425 | 2021-09-04 | 2025-03-14 |
| Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2) CTP-543 matching placebo, CTP-543 - Alopecia Areata | Phase 3 | Completed | Concert Pharmaceuticals | 517 | 2021-06-10 | 2023-07-03 |
| Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) CTP-543 matching placebo, CTP-543 - Alopecia Areata | Phase 3 | Completed | Concert Pharmaceuticals | 706 | 2020-11-23 | 2023-05-03 |
| Long-Term PF-06651600 for the Treatment of Alopecia Areata PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine - Alopecia Areata | Phase 3 | Completed | Pfizer | 1057 | 2019-07-18 | 2026-04-09 |
| A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata Baricitinib, Placebo - Alopecia Areata | Phase 3 | Completed | Eli Lilly and Company | 606 | 2019-07-08 | 2026-04-07 |
| Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata CTP-543 - Alopecia Areata | Phase 2 / Phase 3 | Active not recruiting | Sun Pharmaceutical Industries, Inc. | 1000 | 2019-04-04 | 2025-10-22 |
Showing 20 of 28. Sign in to see all of them.
Alopecia (6) · Alopecia universalis (5) · Hair Diseases (4)
Hypotrichosis (28) · Skin Diseases (28) · Skin and Connective Tissue Diseases (28) · Hair Diseases (24) · Alopecia (22) · Pathological Conditions, Anatomical (6) · Pathological Conditions, Signs and Symptoms (6)
upadacitinib (3) · PF-06651600 (2) · baricitinib (2) · Bexarotene (1) · Interleukin-2 (1) · Methotrexate (1) · Ointments (1) · Tetanus Toxoid (1) · Vaccines (1) · diphenylcyclopropenone (1) · ivarmacitinib (1) · tofacitinib (1)
Pfizer (6) · AbbVie (3) · Sun Pharmaceutical Industries, Inc. (3) · Concert Pharmaceuticals (2) · Eli Lilly and Company (2) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (2) · Centre Hospitalier Universitaire de Nice (1) · Elena Pope (1) · Jinnah Hospital (1) · Legacy Healthcare SA (1) · M.D. Anderson Cancer Center (1) · Reistone Biopharma Company Limited (1) · Sun Pharma Japan Limited (1) · The Hospital for Sick Children (1) · University Hospital, Rouen (1)
United States (16) · Japan (12) · Canada (11) · China (11) · France (9) · Poland (9) · Spain (9) · South Korea (7) · Germany (6) · Taiwan (6) · United Kingdom (6) · Australia (5) · Czechia (5) · Argentina (4) · Hungary (4)
Colin Macarthur, MBChB, PhD (1) · Elena Pope, MD, MSc (1) · Ishad Aggarwal, Dr (1) · Jason Wu (1) · Jianzhong Zhang, PhD (1) · Madeleine Duvic, MD (1) · Maria Hordinsky, MD (1) · Maya Milanova, Dr (1)
PMID 35334197, PMID 36763878, PMID 36855020, PMID 37381691, PMID 37556146, PMID 37991697, PMID 38263353, PMID 38904749, PMID 39962358, PMID 40214720, PMID 41917311, PMID 42481842, PMID 42823604, PMID 42825995, PMID 24226568, PMID 24940651, PMID 28139263, PMID 28300084, PMID 29273099, PMID 31799258, PMID 32941917, PMID 34211288, PMID 36177791, PMID 36884234, PMID 37062298, PMID 37339501, PMID 37403610, PMID 37521227, PMID 37707764, PMID 37917289, PMID 37955531, PMID 39053611, PMID 39141364, PMID 39254890, PMID 39328096, PMID 39423930, PMID 39432738, PMID 39441519, PMID 39846397, PMID 40261547, PMID 40668972, PMID 40976531, PMID 41005700, PMID 41083802, PMID 41317911, PMID 41579233, PMID 41645877, PMID 42584887
2023 (2), 2018 (1), 2025 (1)